Prescription medicine
Eptinezumab Brand names: Vyepti
Eptinezumab (Vyepti) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the eptinezumab FDA label on DailyMed (effective June 5, 2026); every eptinezumab label on DailyMed.
Highlights of the record
FDA label of June 5, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageVYEPTI is indicated for the preventive treatment of migraine in adults.
Forms and strengths
- 100 mg/ml
Injection.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 9,047 through July 30, 2026
What is eptinezumab used for?
From the label: indications and usageVYEPTI is indicated for the preventive treatment of migraine in adults. VYEPTI is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults
Conditions named in the indications of eptinezumab's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Calcitonin Gene-related Peptide Antagonist.
Source: FDA drug label (Vyepti), Lundbeck Pharmaceuticals LLC, effective June 5, 2026 (SPL set 79065861-6aa5-4d1f-829f-3a6471286b36), via openFDA; the full label on DailyMed
Is there a generic for eptinezumab (Vyepti)?
No generic eptinezumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for eptinezumab?
The FDA Adverse Event Reporting System holds 9,047 reports that list eptinezumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 63 are coded as a death and 686 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2024 (2,246, against a median of 156 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Eptinezumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other